The aim of the study is to analyze whether the administration of a vaccine against COVID19 infection can reduce the symptoms of long COVID.

Phase 1

• Conditions: nlike what happens with other respiratory viruses, in a significant proportion of patients who have suffered from the disease, general and multi-organ symptoms may persist for months, which has been called long COVID; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2021-003331-28-ES
• Lead Sponsor: Felix Gutierrez Rodero

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-06-21
• Last Update Posted: 10 August 2021

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 776

Inclusion Criteria

Adults (=18 years) admitted for COVID-19 who continue with moderate or severe symptoms collected in the COVID-19 Symptom Questionnaire” three months after hospital discharge and who sign the informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 776
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-Patients who have received any dose of any of the COVID-19 vaccines.
-Contraindication for the COMIRNATY vaccine according to the technical data sheet.
-Women who are pregnant or intend to become pregnant during the next three months after the administration of the vaccine.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified